financetom
Business
financetom
/
Business
/
General Motors Approves New $6 Billion Buyback Plan; Move Seen Strengthening Earnings Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
General Motors Approves New $6 Billion Buyback Plan; Move Seen Strengthening Earnings Outlook
Jun 11, 2024 8:24 AM

11:07 AM EDT, 06/11/2024 (MT Newswires) -- General Motors' ( GM ) new $6 billion share-repurchase authorization announced Tuesday, along with plans to exhaust a prior buyback program before the end of the second quarter, could strengthen the company's earnings per share outlook, according to Tudor, Pickering, Holt.

GM said it will begin executing on the new authorization when its $10 billion accelerated share-repurchase program announced in November is completed.

The company repurchased $300 million shares in the first quarter and expects to buy back the remaining $1.1 billion left in a prior authorization this month. In the first half of 2024, GM expects to reach $1.7 billion in shareholder returns that includes both buybacks and dividends.

"We are very focused on the profitability of our (internal combustion engine) business, we're growing and improving the profitability of our (electric vehicle) business and deploying our capital efficiently," Chief Financial Officer Paul Jacobson said in a statement. "This allows us to continue returning cash to shareholders."

TPH energy analyst Matt Portillo said in a Tuesday note that GM remains the brokerage's top pick within its auto coverage. He reiterated a buy rating and $62 price target on the stock. Shares of GM were up 1.2% in recent trading.

With GM trading at a 4.7-times price-to-earnings ratio on TPH's 2024 numbers, "allocating more dollars to returning capital via this avenue makes a lot of sense and should strengthen the outlook for EPS going forward while giving management the ability to continue taking down shares opportunistically with (free cash flow)," Portillo said.

Heading into the company's second-quarter, Portillo said TPH is slightly ahead of consensus for adjusted earnings per share at $2.65 versus Wall Street's $2.55 view. GM in April affirmed its 2024 adjusted EPS guidance range of $8.50 to $9.50.

"The investments GM made in its brands and product portfolio over the last several years, and the company's operating discipline, are delivering consistently strong revenue growth, margins and free cash flow," Jacobson said.

Price: 48.21, Change: +0.64, Percent Change: +1.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved